Prognosis
Moderna Bears Face Possible Squeeze on Covid Vaccine Results
- Interim early look at trial results expected this month
- The stock is the largest biotech short play in the sector
This article is for subscribers only.
Bearish investors are holding on to their short bets on Moderna Inc. even as the biotech’s market value swelled by more than $25 billion this year on optimism its experimental messenger-RNA vaccine will play a part in tamping down the pandemic.
Options data suggest the stock is ready for another double-digit swing over the next few weeks and with S3 Partners data showing about $1.84 billion shares shorted, bears might face fresh pain or finally claw back some losses.